JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer
NovoCure Announces Publication Of Data Analysis From Phase 3 PANOVA-3 Trial
NovoCure (NVCR) Stock May Trade At A Discount Despite FDA Setback
FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31
Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19
Novocure denied FDA approval for metastatic cancer treatment
Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Novocure Receives Not Approvable Letter From FDA In Response To PMA Application For Optune Mya For Treatment Of Adult Patients With Brain Metastases From Non-Small Cell Lung Cancer Following Stereotactic Radiation
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
NovoCure: 3 Key Takeaways for Long-Term Investors
NovoCure Limited 2026 Q3 - Results - Earnings Call Presentation
NovoCure (NVCR) Q3 Results Spark Margin Turn Debate
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15
NovoCure Stock Is In Focus After Earnings Beat And Slower Optune Pax Launch
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20
NovoCure Q3 Earnings Call Highlights
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
NovoCure (NVCR) Q3 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.